Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 13/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9025417 | 1.00 | TACR1 (0.52) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL8546078 | 0.99 | MEN1 (0.53) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL9025318 | 0.81 | KCNH2 (0.42) | CYP1A2CYP2D6MEN1KMT2ACYP2C9 | |
| SCHEMBL24310072 | 0.79 | KCNH2 (0.57) | KCNH2 | |
| Hydrochloric Acid SCHEMBL9024656 | 0.79 | MEN1 (0.43) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2706723 | 0.77 | HTR2C (0.56) | CYP1A2CYP2D6MEN1KMT2ACYP2C9 | |
| SCHEMBL2706706 | 0.74 | CYP2D6 (0.44) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9583353 | 0.73 | HTR2C (0.58) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30096915 | 0.73 | HTR2C (0.58) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27326493 | 0.73 | CYP2D6 (0.42) | TACR1TP53CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3016642-B1 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I | EUSTRALIS PHARMACEUTICALS LTD TRADING AS PRESSURA NEURO (AU) | 2019-03-13 | — | — | EP | disclosed |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2019-02-12 | — | — | US | disclosed |
| US-20180071333-A1 | BRAIN, SPINAL, AND NERVE INJURY TREATMENT | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2018-03-15 | — | — | US | disclosed |
| US-20160030474-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2016-02-04 | — | — | US | disclosed |
| US-9186404-B2 | Brain, spinal and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2015-11-17 | — | — | US | disclosed |
| US-20100311803-A1 | METHOD FOR REDUCING INFLAMMATORY RESPONSES AND INFLAMMATION | ADELAIDE RESEARCH & INNOVATION PTY LTD | 2010-12-09 | — | — | US | disclosed |
| US-20100305183-A1 | METHOD AND COMPOSITION FOR REDUCING REPERFUSION INJURY | ADELAIDE RESEARCH & INNOVATION PTY LTD | 2010-12-02 | — | — | US | disclosed |
| US-20100184819-A1 | METHOD FOR REDUCING INTRACRANIAL PRESSURE | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2010-07-22 | — | — | US | disclosed |
| US-20090253698-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2009-10-08 | — | — | US | disclosed |
| US-20060228752-A1 | Genetic polymorphisms in the preprotachykinin gene | FOERNZLER DOROTHEE | 2006-10-12 | — | — | US | disclosed |
| US-20050107380-A1 | Brain, spinal and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2005-05-19 | — | — | US | disclosed |
| EP-1472377-A2 | GENETIC POLYMORPHISMS IN THE PREPROTACHYKININ GENE | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| EP-1261335-A4 | BRAIN, SPINAL AND NERVE INJURY TREATMENT | HOFFMANN LA ROCHE (CH) | 2004-09-22 | — | — | EP | disclosed |
| EP-1385577-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENIGN PROSTATIC HYPERPLASIA | F. Hoffman-la Roche AG (CH) | 2004-02-04 | — | — | EP | disclosed |
| US-20030158187-A1 | Isolated nucleic acids, a diagnostic kit, sequence identification, gene sequence determination, a computer program with stored sequence information | F. HOFFMANN-LA ROCHE AG A SWISS COMPANY (CH) | 2003-08-21 | — | — | US | disclosed |
| WO-2003064685-A2 | GENETIC POLYMORPHISMS IN THE PREPROTACHYKININ GENE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-07 | — | — | WO | disclosed |
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | disclosed |
| EP-1261335-A1 | BRAIN, SPINAL AND NERVE INJURY TREATMENT | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| WO-2002085458-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENIGN PROSTATIC HYPERPLASIA | F. HOFFMAN-LA ROCHE AG (CH) | 2002-10-31 | — | — | WO | disclosed |
| WO-2001052844-A1 | BRAIN, SPINAL AND NERVE INJURY TREATMENT | F. HOFFMANN-LA ROCHE AG (CH) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071333-A1 | BRAIN, SPINAL, AND NERVE INJURY TREATMENT | TACR1, TACR2, NPSR1 | TACR1 1/4885TP53 4473/4885CYP1A2 2551/4885 |
| US-20050107380-A1 | Brain, spinal and nerve injury treatment | TACR1, TACR2, NMUR1 | TACR1 1/4885TP53 4366/4885CYP1A2 2992/4885 |
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | KLK3, TACR1, TACR2 | TACR1 2/4885TP53 1288/4885CYP1A2 1376/4885 |
| US-20160030474-A1 | Brain, Spinal and Nerve Injury Treatment | TACR1, TACR2, NMUR1 | TACR1 1/4885TP53 4366/4885CYP1A2 2992/4885 |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | TACR1, TACR2, NPSR1 | TACR1 1/4885TP53 4473/4885CYP1A2 2551/4885 |
| US-20090253698-A1 | Brain, Spinal and Nerve Injury Treatment | TACR1, TACR2, NMUR1 | TACR1 1/4885TP53 4366/4885CYP1A2 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.